Comparison

Ketamine vs psilocybin (research-stage)

Psilocybin is an investigational psychedelic with active depression research. Ketamine is legally available in clinical settings; psilocybin is not, outside research and limited regulated programs.

Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: June 4, 2026Evidence: Educational synthesis - not medical advice

This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.

Quick answer

Bottom line

Different drugs, different legal status. Ketamine is clinically available now; psilocybin remains primarily investigational. Do not self-medicate.

This page compares Ketamine and Psilocybin across the same fixed dimensions - mechanism, evidence, onset, duration, side effects, access, suitability, and limits. It does not name a winner and does not recommend either option for you.

Related on Ketalux

Ketamine

Psilocybin

Mechanism

NMDA-receptor antagonism.

Serotonin 5-HT2A receptor agonism.

Evidence

Clinical use today; active research.

Phase 2/3 research; not FDA-approved as of mid-2026 for general depression treatment.

Onset

Hours to days.

Often within days to weeks after a session, in research settings.

Duration

Days to weeks.

Weeks to months in studies.

Side effects

Dissociation, BP changes, nausea.

Anxiety, perceptual changes, nausea; longer duration of acute effects.

Access

Specialty clinics today.

Research, Oregon/Colorado regulated programs, and limited international contexts.

Best for

Patients seeking a clinically available rapid-acting option.

Research participants or patients in regulated programs; not a substitute for clinical care.

Limits

Cost, durability, access.

Legal status, limited access, longer sessions.

Disclaimer

This comparison is educational and general. It is not a recommendation. Treatment choice depends on your individual history, diagnosis, prior response, preferences, and access - discuss with a qualified clinician.

About the author

Ira Zoot

Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.